Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer
Autore:
Osman, I; Scher, HI; Drobnjak, M; Verbel, D; Morris, M; Agus, D; Ross, JS; Cordon-Cardo, C;
Indirizzi:
Mem Sloan Kettering Canc Ctr, Dept Pathol, Div Mol Pathol, New York, NY 10021 USA Mem Sloan Kettering Canc Ctr New York NY USA 10021 New York, NY 10021 USA Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, Dept Med, New York, NY 10021 USA Mem Sloan Kettering Canc Ctr New York NY USA 10021 New York, NY 10021 USA Mem Sloan Kettering Canc Ctr, Dept Biostat & Epidemiol, New York, NY 10021USA Mem Sloan Kettering Canc Ctr New York NY USA 10021 New York, NY 10021USA Albany Med Coll, Dept Pathol & Lab Med, Albany, NY 12208 USA Albany Med Coll Albany NY USA 12208 athol & Lab Med, Albany, NY 12208 USA
Titolo Testata:
CLINICAL CANCER RESEARCH
fascicolo: 9, volume: 7, anno: 2001,
pagine: 2643 - 2647
SICI:
1078-0432(200109)7:9<2643:H(PEIT>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
IN-SITU HYBRIDIZATION; GENE AMPLIFICATION STATUS; GROWTH-FACTOR RECEPTOR; DIFFERENTIATION FACTOR; C-ERBB-2 ONCOPROTEIN; ANDROGEN RECEPTOR; POOR-PROGNOSIS; BLADDER-CANCER; CYCLIN D1; P53;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
40
Recensione:
Indirizzi per estratti:
Indirizzo: Cordon-Cardo, C Mem Sloan Kettering Canc Ctr, Dept Pathol, Div Mol Pathol,1275 York Ave, New York, NY 10021 USA Mem Sloan Kettering Canc Ctr 1275 York Ave New York NY USA 10021
Citazione:
I. Osman et al., "HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer", CLIN CANC R, 7(9), 2001, pp. 2643-2647

Abstract

Purpose: Amplification of HER-2/neu gene and overexpression of its encodedproduct, the p185neu (HER-2/neu) tyrosine kinase membrane receptor, have been associated with tumor progression in certain neoplasms. We conducted this study to investigate patterns of HER-2/neu protein expression in prostate cancer, analyzing different points in the natural and treated history of the disease. Experimental Design: Radical prostatectomy cases (83) and 20 metastatic lesions were studied for the association between HER-2/neu protein overexpression detected by immunohistochemistry and clinicopathological parameters, including time to prostate-specific antigen (PSA) relapse. Results: HER-2/neu protein overexpression, defined as complete membrane staining in > 10% of tumor cells using the Food and Drug Administration-approved Dako kit, was found in 9 of 45 (20%) of evaluable hormone naive primarytumors and 23 of 34 (67%) primary tumors after androgen-deprivation therapy (P = 0.0001). Of the 20 metastatic lesions, positivity was noted in 16 (80%) of the cases. On univariate analysis, HER-2/neu overexpression was associated with pretreatment PSA (P = 0.011) and time to PSA relapse (P = 0.02). After controlling for pretreatment PSA, the association between hormone treatment and HER-2/neu was still observed. No association was found betweenHER-2/neu overexpression and Gleason score, capsular invasion, and tumor proliferative index determined by Ki67. Conclusions: These data suggest that there is significant HER-2/neu overexpression in primary tumors that persist after androgen deprivation. It alsoemphasizes the importance of characterizing tumors at determined points inthe natural or treated history of prostate cancer when targeting treatmentto specific biological processes.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/11/20 alle ore 10:15:29